Gene-Gene Interaction between APOA5 and USF1: Two Candidate Genes for the Metabolic Syndrome by Singmann, Paula et al.
Original Article
Obes Facts 2009;2:235–242 Published online: July 20, 2009
DOI: 10.1159/000227288
Dr. Thomas Illig
Institute of Epidemiology
Helmholtz Zentrum München
German Research Center for Environmental Health (GmbH)
Ingolstädter Landstraße 1, 85764 Neuherberg, Germany
illig@helmholtz-muenchen.de
© 2009 S. Karger GmbH, Freiburg
Accessible online at: 
www.karger.com/ofa
Fax +49 761 4 52 07 14
Information@Karger.de
www.karger.com
Gene-Gene Interaction between APOA5 and USF1: Two 
Candidate Genes for the Metabolic Syndrome
Paula Singmanna Jens Baumerta Christian Herderb Christa Meisingera Christina Holzapfela,c  
Norman Kloppa H.-Erich Wichmanna,d Martin Klingenspore Wolfgang Rathmannf  
The KORA group Thomas Illiga+ Harald Grallerta+
a  Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, 
b  Insitute for Clinical Diabetes Research, German Diabetes Center, Leibniz Institute at Heinrich-Heine-University, Düsseldorf,
c  Else Kröner-Fresenius Center for Nutritional Medicine, Technical University of Munich,
d  Chair of Epidemiology, IBE, Ludwig-Maximilians-University Munich,
e  Molecular Nutrional Medicine, Else Kröner-Fresenius Center at Technical University of Munich,
f  Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute at Heinrich-Heine-University, Düsseldorf, Germany
Key Words 
Metabolic syndrome · Cardiovascular risk · SNP ·  
APOA5 · USF1 
Summary
Objective: The metabolic syndrome, a major cluster of 
risk factors for cardiovascular diseases, shows increasing 
prevalence worldwide. Several studies have established 
associations of both apolipoprotein A5 (APOA5) gene 
variants and upstream stimulatory factor 1 (USF1) gene 
variants with blood lipid levels and metabolic syndrome. 
USF1 is a transcription factor for APOA5. Methods: We 
investigated a possible interaction between these two 
genes on the risk for the metabolic syndrome, using 
data from the German population-based KORA survey 
4 (1,622 men and women aged 55–74 years). Seven 
APOA5 single nucleotide polymorphisms (SNPs) were 
analyzed in combination with six USF1 SNPs, applying 
logistic regression in an additive model adjusting for age 
and sex and the definition for metabolic syndrome from 
the National Cholesterol Education Program’s Adult 
Treatment Panel III (NCEP (AIII)) including medication. 
Results: The overall prevalence for metabolic syndrome 
was 41%. Two SNP combinations showed a nominal 
gene-gene interaction (p values 0.024 and 0.047). The ef-
fect of one SNP was modified by the other SNP, with a 
lower risk for the metabolic syndrome with odds ratios 
(ORs) between 0.33 (95% CI = 0.13–0.83) and 0.40 (95% 
CI = 0.15–1.12) when the other SNP was homozygous for 
the minor allele. Nevertheless, none of the associations 
remained significant after correction for multiple testing. 
Conclusion: Thus, there is an indication of an interaction 
between APOA5 and USF1 on the risk for metabolic syn-
drome.
Introduction
The prevalence of the metabolic syndrome has increased in 
epidemic proportions worldwide [1]. Apolipoprotein A5 
(APOA5) and upstream stimulatory factor 1 (USF1) are 
genes both related to metabolic syndrome or its characteristic 
traits [2].
APOA5 is an apolipoprotein discovered independently by 
two separate research groups [3, 4] in 2001. The correspond-
ing gene is located on chromosome 11 in the APOA1/C3/A4/
A5 gene cluster. The APOA5 locus is linked to familial com-
bined hyperlipidemia (FCHL) and elevated triglyceride (TG) 
levels, a known risk factor for cardiovascular diseases (CVD) 
[5]. FCHL is the most common inherited dyslipidemia with a 
prevalence of 1–2% in western populations and of about 20% 
in patients with premature coronary heart disease (CHD) [6]. 
The key role of APOA5 in the regulation of TG levels has 
been supported by several epidemiologic and functional stud-
ies [7] and confirmed in different ethnic groups, e.g. in Cauca-
sians, Japanese, and Chinese [8].
USF1 is localized on chromosome 1 in another locus linked 
to FCHL [9]. It encodes for a ubiquitously expressed tran-
scription factor that regulates some 40 genes involved with 
or actually crucial to glucose and fat metabolism [10]. USF1 +These authors contributed equally to the work.
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belongs to the family of basic helix-loop-helix leucine zipper 
transcription factors, dimerizes – most often with USF2 – and 
binds to palindromic E-box sequence in the promoter area of 
its target genes. Thus it activates transcription in response to 
different stimuli. APOA5 belongs to that group of genes regu-
lated by USF; insulin stimuli reduce the association of USF1 
transcription factor to APOA5 E-box [11]. Associations be-
tween USF1 variants and FCHL [9] and associations of USF1 
SNPs with TG levels and low density lipoprotein (LDL) lev-
els in blood [2] have been found. Associations with CVD and 
overall mortality in women also have been shown [12].
The changes in blood lipid levels for APOA5 and USF1 de-
scribed above occur similarly in the metabolic syndrome, an 
important risk factor of CHD morbidity and mortality [2].
Main effects of APOA5 [7] and USF1 were already inves-
tigated in KORA S4 [13]. Grallert et al. [7] found significant 
effects of APOA5 SNPs on two features of the metabolic 
syndrome, namely elevated TG levels and lowered HDL lev-
els, but no effects on metabolic syndrome itself. The effects 
of USF1 SNPs were investigated by Holzapfel et al. [13] who 
showed an association with lowered LDL levels.
Having both environmental and genetic risk factors [1], the 
syndrome’s genetic background was our focus. We have ex-
amined a potential gene-gene interaction (i.e. deviation from 
the summation of single effects) between APOA5 and USF1 
and the metabolic syndrome using data from a large popula-
tion-based study sample from southern Germany. 
Material and Methods
Study Population
Data were drawn from the KORA study (Cooperative Health Research 
in the Region of Augsburg, Germany). KORA was initiated in the Augs-
burg region in 1996 as a research platform for population-based studies 
[14, 15]. In detail, we used data of the S4 survey that was performed from 
1999 to 2001 and in which information about the participants’ cardiovas-
cular risk factors was obtained. KORA S4 included 1,653 participants of 
the 55- to 74-year age group. Overall, 1,622 subjects (829 men and 793 
women) were genotyped successfully and comprised the study population 
of our analyses. Among those, 1,353 subjects participated in an oral glu-
cose tolerance test (OGTT); in the remaining 269 subjects only fasting 
glucose levels were measured.
Genotyping
Seven SNPs of the APOA5 gene and six SNPs of the USF1 gene, geno-
typed in KORA S4, were used to investigate the hypothesized gene-
gene interaction with the risk of having the metabolic syndrome (table 
1). SNPs were selected both on functional (e.g. in or near exons, in pro-
moter regions) and positional (distance <5 kb where possible) basis with 
simultaneous consideration of validation and frequency. SNPs containing 
the same information (r2 ≥ 0.8) were excluded. Further information like 
minor allele frequencies, LD plots, and SNP position in the genes had 
been published in [7] (also see online supplement) for APOA5 and in [13] 
for USF1 and are also partly available in table 1.
Genotyping was performed with matrix-assisted laser desorption ioni-
zation-time of flight mass spectrometry (MALDI-TOF MS) as described 
elsewhere [16]. Assessing the Hardy-Weinberg equilibrium (HWE) 
with an exact test using a permutation approach developed by Guo and 
Thompson [17] revealed that no SNP departed from HWE (table 1). 
Genotyping succeeded with call rates greater than 94.0%, and discord-
ance was less than 0.5% in 210 routine duplicates in KORA S4 [7, 13]. 
Definition of the Metabolic Syndrome
The metabolic syndrome was diagnosed using the definition provided by 
the National Cholesterol Education Program’s Adult Treatment Panel III 
(NCEP (AIII)) including medication [adapted from 18] (table 2).
Statistics
The risk for having the metabolic syndrome was estimated by logistic 
regression and the assumption of an additive genetic model. Risks were 
displayed as odds ratios (ORs) with 95% confidence intervals (95% CI). 
Adjustment for age and sex was performed. To assess the gene-gene in-
teraction, i.e. whether the metabolic syndrome risk of one SNP was modi-
fied by another SNP, we included both SNPs and additionally an interac-
tion term of both SNPs in each model. Therefore, we combined the seven 
APOA5 SNPs with the six USF1 SNPs and performed the respective logis-
tic regression leading to 42 different models. Each SNP was coded as 0 for 
homozygous major allele, as 1 for heterozygous, and as 2 for homozygous 
minor allele. The OR of having a metabolic syndrome per copy of the 
minor allele for the first SNP (SNP 1) by the value of the other SNP (SNP 
2) was drawn from this regression and calculated by exp[estimate(SNP 
1) + estimate(SNP 1 × SNP 2) × value(SNP 2)]. The respective 95% CIs 
were drawn from the logistic regression using the regression coefficients 
and the covariance matrix. 
Furthermore, we performed additional analyses with five quantitative 
traits of the metabolic syndrome (waist circumference, HDL cholesterol, 
TG levels, fasting blood glucose, and blood pressure) as endpoints using 
separate linear regression models. Again, we estimated 42 different mod-
els for each of the five quantitative traits with age  and sex adjustment in-
cluding the two SNPs and an interaction term of both SNPs. The increase 
of the mean quantitative trait per copy of the minor allele for the first 
SNP (SNP 1) by the value of the other SNP (SNP 2) was drawn from this 
regression and calculated by estimate(SNP 1) + estimate(SNP 1 × SNP 2) 
× value(SNP 2) and vice versa for SNP 2. The respective 95% CIs were 
drawn from the linear regression using the regression coefficient and the 
covariance matrix. 
We assumed interaction effects with p values less than 0.05 as statisti-
cally significant. Bonferroni correction for multiple testing was done with 
a corrected significance level of 0.001 (alpha of 0.05/7 APOA5-SNPs × 6 
USF1-SNPs). All calculations were conducted with the statistical software 
SAS (SAS V. 9.1 Cary, NC, USA). 
Results
The prevalence of the metabolic syndrome according to NCEP 
(AIII) definition was 41.1% in the overall study population. 
Most frequently the participants achieved one or two of the 
five criteria for the metabolic syndrome (24.4 or 23.8%); only 
11% of the study population revealed none of the syndrome’s 
characteristics. The most often met criterion for the metabolic 
syndrome was ‘elevated blood pressure or antihypertensive 
drug treatment’ (1,197 persons (74.1% of all participants)) 
followed by large waist circumference (790 persons (48.8%)), 
lowered HDL cholesterol (655 participants (40.8%)), elevated 
TG levels (479 persons (29.6%)), and raised blood glucose lev-
els (425 individuals (26.6%))). According to this observation, 
antihypertensive drugs were the most frequently taken drugs 
in the study population (37.2% of the participants compared 
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with 2.1% receiving insulin treatment, 5.2% receiving oral an-
tidiabetic drug treatment, and 12.2% receiving lipid lowering 
drug application) (table 3).
The logistic regression analysis revealed overall a lower risk 
for the metabolic syndrome for one SNP per each copy of the 
minor allele of the other SNP. We performed this analysis to 
assess the interaction between two SNPs on the risk of having 
a metabolic syndrome. Two SNP × SNP interactions changing 
the risk for the metabolic syndrome were nominal on a signifi-
cance level of 0.05. These interactions were observed between 
polymorphisms rs2516839 and rs3135506 (p = 0.0473), and be-
tween rs2073658 and rs1729411 (p = 0.0243). The first SNP of 
a combination denotes the USF1 gene and the second SNP 
denotes the APOA5 gene, what is pursued in the text.
All of those combinations were associated inversely with 
the risk for the metabolic syndrome, with increasing numbers 
Table 1. Characteristics of the SNPs included in the analyses
SNPa 
(dbSNP name)
Function/region  of SNP Genotype Frequency ( %)  
[frequency among MetS probands (%)]
HWE, p 
value
major allele ho-
mozygous
heterozygous minor allele  
homozygous
USF1
rs2774279 synonymousb / exon 12 of ARHGAP30 C>T 675 (42.19) 
[381 (40.92)]
733 (45.81) 
[441 (47.37)]
192 (12.00) 
[109 (11.71)]
0.75
rs10908821 intron 1 / 3’UTR C>G 1216 (75.91) 
[708 (75.97)]
358 (22.35) 
[207 (22.21)]
28 (1.75) 
[17 (11)]
0.78
rs2073658 intron 7 G>A 814 (50.75) 
[461 (49.36)]
666 (41.52) 
[397 (42.51)]
124 (7.73) 
[76 (8.14)]
0.45
rs2774276 intron 5 G>C 944 (58.89) 
[556 (59.53)]
572 (35.68) 
[325 (34.8)]
87 (5.43) 
[53 (5.67)]
0.98
rs2516839 5‘ UTR/ exon 2 A>G 652 (40.78) 
[393 (42.3)]
737 (46.09) 
[424 (45.64)]
210 (13.13) 
[112 (12.06)]
0.94
rs1556259 3‘ near gene of USF1 / intron 1 T>C 1217 (75.92) 
[721 (77.28)]
356 (22.21) 
[ 197 (21.11)]
30 (1.87) 
[15 (1.61)]
0.51
APOA5
rs2542061 intergenic region A>G 398 (25.17) 
[223 (24.32)]
795 (50.28) 
[469 (317)]
388 (24.54) 
[225 (24.54)]
0.82
rs633867 3‘ UTR C>T 1,493 (95.77) 
[877 (96.37)]
65 (4.17) 
[32 (3.52)]
1 (0.06) 
[1 (0.11)]
0.74
rs1729411 promoter region G>A 1,188 (74.76) 
[688 (74.38)]
379 (23.85) 
[223 (24.11)]
22 (1.38) 
[14 (1.51)]
0.18
rs662799 promoter A>G 1,376 (85.63) 
[817 (87.38)]
218 (13.57) 
[113 (12.09)]
13 (0.81) 
[5 (0.53)]
0.18
rs619054 3‘ UTR in exon 3 G>A 872 (54.23) 
[499 (53.31)]
627 (38.99) 
[372 (39.74)]
109 (6.78) 
[65 (6.94)]
0.80
rs3135507 missenseb (Met>Val)/ exon 3 C>T 1,500 (94.04) 
[876 (94.4)]
94 (5.89) 
[51 (5.5)]
1 (0.06) 
[1 (0.11)]
0.70
rs3135506 missenseb (Trp>Ser)/ exon 2 signal peptide G>C 1,360 (88.71) 
[809 (89.89)]
165 (10.76) 
[89 (9.89)]
8 (0.52) 
[2 (0.22)]
0.22
aBold SNPs are enclosed in the significant combinations in the overall study population.
bAmino acid change due to SNP.
Waist circumference > 102 cm (men) or >88 cm (women)
HDL cholesterol level < 1.04 mmol/l (men) or <1.29 mmol/l (women) or treatment with lipid 
lowering drugs
Triglyceride level ≥ 1.7145 mmol/l or treatment with lipid lowering drugs
Fasting glucose ≥ 110 mg/dl or ensured diabetic (OGTT) or treatment with oral antidiabetics or 
insulin
Blood pressure ≥130 / ≥85 mm Hg or treatment with antihypertensive drugs
aAt least any three criteria out of five lead to classification of metabolic syndrome. 
Table 2. Definition of the metabolic syndrome 
from NCEP(AIII) including medicationa
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of the minor alleles of APOA5 and USF1. For the case with 
the lowest p value for interaction, rs2073658 × rs1729411, the 
OR of having a metabolic syndrome per copy of the minor al-
lele for rs2073658 by rs1729411 was 0.81 (95% CI = 0.67–0.97) 
in homozygous state for the major allele (GG), 0.54 (95% CI 
= 0.34–0.86) in heterozygous state (GA); and 0.36 (95% CI = 
0.16–0.81) in homozygous state for the minor allele (AA) (table 
4). Conversely, for rs1729411, the OR was 0.74 (95% CI = 0.55–
0.99) with rs2073658 in homozygous state for the major allele 
(GG); 0.49 (95% CI = 0.27–0.89) in heterozygous state (GA); 
and 0.33 (CI = 0.13–0.83) in homozygous state for the minor al-
lele (AA). All other ORs are presented in table 4. These results 
did not remain nominal after Bonferroni correction.
Moreover, we performed a sex-stratified analysis and ob-
tained different trends for associations of SNPs combinations 
compared to the overall analysis – in contrast to the overall 
analysis all of them associated with higher risk of metabolic 
syndrome presented with the minor alleles of APOA5 and 
USF1. Due to the stratification, the number of cases decreased 
accordingly (partially even no case with homozygous minor 
allele for both SNPs), and thus ORs were very high (data not 
shown). Consequently, these results were not processed fur-
ther, because of their uncertainty.
Furthermore, the quantitative traits of the metabolic syn-
drome were applied for analysis. One of the two interactions, 
namely rs2073658 × rs1729411, was also nominally associated 
with waist circumference (table 5). Significances were in a 
comparable dimension as the main analyses and similarly 
failed Bonferroni correction for multiple testing.
We also applied the other model assumptions (domi-
nant, recessive) which revealed very similar results (data not 
shown).
Discussion
Our results from KORA S4 indicate a possible gene-gene in-
teraction between APOA5 and USF1 variants and the meta-
bolic syndrome in two combinations. The results showed a 
trend for association, if we refrained from Bonferroni correc-
tion. Persons who were homozygous for minor alleles in both 
SNPs of one of the found interactions seemed to have a lower 
risk for the metabolic syndrome than those homozygous for 
the major alleles or heterozygous. This conclusion implies 
that individuals with the homozygous genotype for the minor 
alleles of both SNPs of a found interaction combination have 
the lowest risk for metabolic syndrome in this context (ORs 
ranged between 0.33 and 0.40; table 4). 
To our knowledge, these associations have not been inves-
tigated before.
According to Moore and Williams [19] gene-gene interac-
tions play a relevant role in the genetic architecture of com-
mon complex diseases and can be seen from statistical and 
from biological view. Stating a relationship between those 
views occurs as a great challenge thereby. As we focused on a 
statistical interaction on population level we merely consider 
some aspects subsequently about explanations of the statisti-
cal effect and about biological plausibility. 
Table 3. Descriptive data of the study population
Number of participantsa Mean ± standard deviation
overall women men overall women men
Age, years 1,622 793 829 64 ± 5  
(range 55–74)
Waist circumference, cm 1,622 793 825 96.1 ± 11.8 91.0 ± 11.6 101.0 ± 9.8
HDL, mmol/l 1,620 792 828 1.49 ± 0.42 1.63 ± 0.44 1.35 ± 0.35
TG, mmol/l 1,620 785 820 1.49 ± 1.07 1.53 ± 1.00 1.76 ± 1.13
Fasting glucose, mg/dl 1,618 791 827 108 ± 33 105 ± 33 111 ± 32
Blood pressure, mm Hg 1,616 791 825 136.5 ± 20.5 / 80.5 ± 
10.6
132.3 ± 20.0 / 78.5 
± 10.1
140.5 ± 20.1 / 82.4 
± 10.6
Number of participants (% of all participants)
overall women men
Drug treatmentb 
Insulin 1,617 791 826  33 (2.02%)  19 (2.40%)  14 (1.69%) 
Oral antidiabetics 1,617 791 826  84 (5.19%)  33 (4.17%)  51 (6.17%) 
Lipid lowering drugs 1,617 791 826 197 (12.18%)  89 (11.25%) 108 (13.08%) 
Antihypertensives 1,617 791 826 602 (37.23%) 302 (38.18%) 300 (36.32%) 
Metabolic syndrome (NCEP (AIII)) 1,604 786 818 659 (41.08%) 300 (38.17%) 359 (43.89%)
aNumber of persons used from KORA S4 study
bNumber of persons with defined drug treatment.
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From biological view there is no physical interaction be-
tween USF1 and APOA5 proteins (but protein-DNA in-
terplay), but a statistical interaction may also occur without 
physical interaction of biomolecules, if these have an impact 
on the same phenotype as APOA5 and USF1 do have on 
blood lipid levels.
None of the investigated APOA5 SNPs are located within 
the E-box, where USF dimers physically collaborate with the 
DNA [11]. Therefore the statistical interaction effects did not 
suggest biological plausibility simply by variations at the locus 
of physical interaction by a sequence alteration.
Two of the SNPs included in the interaction calculation 
cause a missense exchange. Namely, these are rs3135506 
(Trp>Ser) and rs3135507 (Met>Val). The missense exchange 
rs3813609 (Val>Leu) is represented by another USF1-SNP 
(rs2516839, which participates in SNP combinations with in-
teraction effect). None of the others change the amino acid 
sequence. SNP rs3135506 alters the cleavage site of signal 
sequence and, thus, lowers translocation and secretion of the 
APOA5 protein [20]. The interaction combination including 
rs3135506 showed the lowest significance of all found nominal 
combinations (p = 0.0473) (table 4). Altogether, amino acid 
changes might contribute to a biological background of the 
statistical effects seen here.
There is seemingly none of the USF1 SNPs located in any 
of the protein domains responsible for dimerization or do-
mains needed for transactivation. Dimerization then might 
not be affected by the variations, but an influence on the com-
plex transcription machinery is conceivable.
Via presence of insulin, USF1/USF2 dimers would be 
phosphorylated and subsequently non-functional for APOA5 
transcription initiation [11]. Maybe the SNP variants influence 
this regulation mechanism positively or negatively and, thus, 
contribute to the interaction effect. 
The major fraction of USF1 functions as heterodimers with 
USF2 [2]. Thus, an influence of USF2 variations on the sug-
gested interaction between APOA5 and USF1 should be con-
sidered. Actually, there are SNPs in the USF2 gene, and one 
of them, rs45614038, even causes a missense mutation (www.
ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId = 7392 and choos-
eRs = all in Jan 2009).
These advisements make us consider that either there are 
yet unknown regulatory regions, where these SNPs are lo-
cated, or the underlying cause is by far more complex than 
variations in any regulatory regions of these genes. So we also 
consider contributions in generating the statistical interac-
tion effect by the very complex regulatory machinery of and 
between APOA5 and USF1 and by other affected genes or 
proteins that take part in the metabolic pathways regulated 
by APOA5 after USF1 stimulation. For example, Prieur et 
al. [21] described an activation of APOA5 synergistically ac-
complished by thyroid hormone receptor and USF1. Further 
examples of regulators of APOA5 are RORa, PPARa, and 
LXR [8]. Recently, Nowak et al. [22] could demonstrate the T
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glucose dependency of APOA5 activation by USF dimers via 
a dephosphorylation mechanism.
The relevance of investigating the connection between 
USF1 and APOA5 was already underlined by a review of 
Naukkarinen et al. [23] in 2006 that summarizes genetic find-
ings on the risk for FCHL. They found both genes with very 
interesting clues not only on the risk for FCHL but also on 
the metabolic syndrome based on the disorders´ overlapping 
molecular pathogenesis.
Gene-gene interaction has already been identified for other 
genes. For example, Pessi et al. [24] found an interaction ef-
fect between FCGR2A and CRP on the intima media thick-
ness in young Finnish men with a lack of independent effects 
of FCGR2A polymorphisms on IMT, and an investigation in 
French Canadians [25] showed significant interaction effect of 
gene variants in the VLDL catabolism.
Overall, we suppose that we have not found the causal or 
functional SNPs for the interaction effect, but possibly mark-
ers for it.
Our study is strengthened by the selection of the participants 
from a large homogeneous population-based sample with high-
quality phenotyping (e.g. anthropometric measures, OGTT). 
However, our findings could be only chance discoveries. It 
should be considered that there were very few participants 
with both USF1 and APOA5 SNPs in homozygous state for the 
minor allele in all found combinations with nominal interactions 
(no individual with GG in rs2516839 and concomitant CC in 
rs3135506; one individual with AA in rs2073658 and concomi-
tant AA in rs1729411, and only a few persons in some hetero-
zygous combinations out of about 1,600 individuals) (data not 
shown). Therefore, our results should be reproduced in larger 
study samples, especially to figure out the sex-stratified effects. 
Moreover, our study population shows a high prevalence 
of the metabolic syndrome compared to numbers reported for 
different populations. This likely might be due to the older 
age and the high mean of the BMI in the group. Day et al. 
[26] also reported a prevalence of 40% with the NCEP (AIII) 
definition in a US group of probands aged 60 to 69 years; thus 
the age effect seems to explain the prevalence we found.
In conclusion, we found a suggestive gene-gene interaction 
between APOA5 and USF1 by statistical analysis of data from 
the KORA study. However, the underlying mechanisms are 
speculative. 
Finally, we would appreciate that other research groups 
resume our work and either replicate our findings in a proper 
and well powered sample or focus on biological causes of the 
found statistical effect.
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